HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Somatropin therapy in italian adults with growth hormone deficiency.

AbstractBACKGROUND:
In adult population, Growth Hormone Deficiency (GHD) is a complex clinical condition with heterogeneity of causes and duration. Growth Hormone (GH) replacement therapy has beneficial effects entailing a chronic and expensive use. Therefore, entity, appropriateness and standardization of GHD treatment need to be accurately analysed. In Italy, the epidemiological surveillance on somatropin therapy is entrusted to the National Register of Growth Hormone Therapy (Registro Nazionale degli Assuntori dell'Ormone della Crescita-RNAOC) by the Italian Regulation, in accordance of which the RNAOC-database is collecting the notifications of somatropin prescriptions.
METHODS:
Aim of this study is to analyse data on somatropin-treated adult population communicated to the RNAOC by the specialist centres of 15 Italian regions and 2 autonomous provinces.
RESULTS:
From 2011 to 2019, the somatropin-treated adults were 970 with 4061 examinations (1.21 ± 0.33 visits/year). The diagnoses were: hypopituitarism (n = 579); hypophysectomy (n = 383); and congenital GHD (n = 3). Five subjects were addressed with diagnoses not included in the regulation. The starting posology of somatropin was 0.320 (± 0.212) mg/day, 0.292 (± 0.167) mg/day in male and 0.360 (± 0.258) in female patients, with 7 administrations/week in 70.31% of the prescriptions. The differences in posology by gender persisted at 10th year of the follow-up. Starting dosage was higher in patients diagnosed with adult GHD before the age of 30 (0.420 ± 0.225 mg/day), with a progressive decrease of the dosage during the follow-up.
CONCLUSIONS:
This is the first report on adult GH treatment, describing numbers, diagnoses, and pharmaceutical prescriptions associated to somatropin therapy in a large cohort of Italian GHD-adults.
AuthorsFlavia Pricci, Daniela Rotondi, Marika Villa, Arianna Valerio, Elvira Agazio, Paolo Roazzi
JournalBMC endocrine disorders (BMC Endocr Disord) Vol. 22 Issue 1 Pg. 52 (Mar 03 2022) ISSN: 1472-6823 [Electronic] England
PMID35241041 (Publication Type: Journal Article)
Copyright© 2022. The Author(s).
Chemical References
  • Recombinant Proteins
  • Human Growth Hormone
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Hormone Replacement Therapy (methods)
  • Human Growth Hormone (administration & dosage, deficiency, therapeutic use)
  • Humans
  • Hypophysectomy
  • Hypopituitarism (diagnosis, drug therapy)
  • Italy
  • Male
  • Middle Aged
  • Recombinant Proteins (therapeutic use)
  • Registries
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: